Wang et al. showed that treatment of HCC cells with the anti-CDH17 antibody Lic5 reduced both total and phosphorylated β-catenin (Thr41/Ser45), downregulated cyclin D1 levels, and increased Rb expression in vitro. Here, CDH17 is linked to hepatocellular carcinoma.